Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
Background. Metastatic uveal melanoma (MUM) is associated with a poor prognosis, with a median overall survival (OS) of 4–15 months. Despite new insights into the genetic and molecular background of MUM, satisfactory systemic treatment approaches are currently lacking. The study results of innovativ...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wiley
2019-01-01
|
| Serie: | Case Reports in Oncological Medicine |
| Accesso online: | http://dx.doi.org/10.1155/2019/3560640 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|